Cytotoxicity screening and cytokine profiling of nineteen nanomaterials enables hazard ranking and grouping based on inflammogenic potential

Nanotoxicology

Volumn 11, Issue 6, 2017, Pages 809-826

  Bhattacharya, Kunal ^a   Kiliç, Gözde ^a   Costa, Pedro M ^a   Fadeel, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

cytotoxicity; hierarchical clustering; in vitro screening; inflammation; Nanomaterials

Indexed keywords

CELL NUCLEUS RECEPTOR; CERIUM OXIDE NANOPARTICLE; CHEMOKINE; CYTOKINE; ENDOTOXIN; LIVER X RECEPTOR; MULTI WALLED NANOTUBE; NANOMATERIAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID X RECEPTOR; ROSIGLITAZONE; SILICA NANOPARTICLE; SILVER NANOPARTICLE; SINGLE WALLED NANOTUBE; ZINC OXIDE NANOPARTICLE; CARBON NANOTUBE;

ARTICLE; CHEMICAL COMPOSITION; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOTOXICITY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RISK ASSESSMENT; ZETA POTENTIAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; DANGEROUS GOODS; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; TOXICITY;

CELL LINE; CELL SURVIVAL; CLUSTER ANALYSIS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HAZARDOUS SUBSTANCES; HUMANS; MACROPHAGES; NANOSTRUCTURES; NANOTUBES, CARBON; PARTICLE SIZE;

EID: 85027882619     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.1080/17435390.2017.1363309     Document Type: Article

References (49)

1. Abitbol T, Rivkin A, Cao Y, Nevo Y, Abraham E, Ben-Shalom T, et al. 2016. Nanocellulose, a tiny fiber with huge applications. Curr Opin Biotechnol 39:76–88.
2. H17 cells in asthma and COPD. Annu Rev Physiol 72:495–516.
3. Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P., 2014. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev 25:57–65.
4. Arend WP., 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13:323–40.
5. Arts JH, Hadi M, Irfan MA, Keene AM, Kreiling R, Lyon D, et al. 2015. A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). Regul Toxicol Pharmacol 71:S1–27.
6. Arts JH, Hadi M, Keene AM, Kreiling R, Lyon D, Maier M, et al. 2014. A critical appraisal of existing concepts for the grouping of nanomaterials. Regul Toxicol Pharmacol 70:492–506.
7. Bhattacharya K, Andón FT, El-Sayed R, Fadeel B., 2013. Mechanisms of carbon nanotube-induced toxicity:focus on pulmonary inflammation. Adv Drug Deliv Rev 65:2087–97.
8. Bhattacharya K, Mukherjee SP, Gallud A, Burkert SC, Bistarelli S, Bellucci S, et al. 2016. Biological interactions of carbon-based nanomaterials:from coronation to degradation. Nanomedicine 12:333–51.
9. Braakhuis HM, Oomen AG, Cassee FR., 2016. Grouping nanomaterials to predict their potential to induce pulmonary inflammation. Toxicol Appl Pharmacol 299:3–7.
10. Braakhuis HM, Park MV, Gosens I, De Jong WH, Cassee FR., 2014. Physicochemical characteristics of nanomaterials that affect pulmonary inflammation. Part Fibre Toxicol 11:18.
11. Catalán J, Ilves M, Järventaus H, Hannukainen KS, Kontturi E, Vanhala E, et al. 2015. Genotoxic and immunotoxic effects of cellulose nanocrystals in vitro. Environ MolMutagen 56:171–82.
12. Cho WS, Duffin R, Bradley M, Megson IL, MacNee W, Lee JK, et al. 2013. Predictive value of in vitro assays depends on the mechanism of toxicity of metal oxide nanoparticles. Part Fibre Toxicol 10:55.
13. Cho WS, Duffin R, Poland CA, Howie SE, MacNee W, Bradley M, et al. 2010. Metal oxide nanoparticles induce unique inflammatory footprints in the lung:important implications for nanoparticle testing. Environ Health tPerspect 118:1699–706.
14. Chow KT, Gale M., 2015. Snapshot:interferon signaling. Cell 163:1808–e1.
15. + T cells. Science 270:1811–15.
16. Dekkers S, Oomen AG, Bleeker EA, Vandebriel RJ, Micheletti C, Cabellos J, et al. 2016. Towards a nanospecific approach for risk assessment. Regul Toxicol Pharmacol 80:46–59.
17. Durán N, Durán M, de Jesus MB, Seabra AB, Fávaro WJ, Nakazato G., 2016. Silver nanoparticles:a new view on mechanistic aspects on antimicrobial activity. Nanomedicine 12:789–99.
18. Fadeel B, Fornara A, Toprak MS, Bhattacharya K., 2015. Keeping it real:the importance of material characterization in nanotoxicology. Biochem Biophys Res Commun 468:498–503.
19. Farcal L, Andón FT, Di Cristo L, Rotoli BM, Bussolati O, Bergamaschi E, et al. 2015. Comprehensive in vitro toxicity testing of a panel of representative oxide nanomaterials:first steps towards an intelligent testing strategy. PLoS One 10:e0127174.
20. Glass CK, Saijo K., 2010. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 10:365–76.
21. Godwin H, Nameth C, Avery D, Bergeson LL, Bernard D, Beryt E, et al. 2015. Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-making. ACS Nano 9:3409–17.
22. Götz AA, Vidal-Puig A, Rödel HG, de Angelis MH, Stoeger T., 2011. Carbon-nanoparticle-triggered acute lung inflammation and its resolution are not altered in PPARγ-defective (P465L) mice. Part Fibre Toxicol 8:28.
23. Hamilton JA., 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8:533–44.
24. Hanif Z, Ahmed FR, Shin SW, Kim YK, Um SH., 2014. Size- and dose-dependent toxicity of cellulose nanocrystals (CNC) on human fibroblasts and colon adenocarcinoma. Colloids Surf B Biointerfaces 119:162–5.
25. Hong C, Tontonoz P., 2008. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 18:461–7.
26. Huizar I, Malur A, Patel J, McPeek M, Dobbs L, Wingard C, et al. 2013. The role of PPARγ in carbon nanotube-elicited granulomatous lung inflammation. RespirRes 14:7.
27. Ihaka R, Gentleman RR., 1995. A language for data analysis and graphics. J. Comput. Graph Stat 5:299–314.
28. Jiang C, Ting AT, Seed B., 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–6.
29. Kang H, Mintri S, Menon AV, Lee HY, Choi HS, Kim J., 2015. Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles. Nanoscale 7:18848–62.
30. Krämer A, Green J, Pollard J, Tugendreich S., 2014. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30:523–30.
31. Landsiedel R, Sauer UG, Ma-Hock L, Schnekenburger J, Wiemann M., 2014. Pulmonary toxicity of nanomaterials:a critical comparison of published in vitro assays and in vivo inhalation or instillation studies. Nanomedicine (Lond) 9:2557–85.
32. Li Y, Boraschi D., 2016. Endotoxin contamination:a key element in the interpretation of nanosafety studies. Nanomedicine (Lond) 11:269–87.
33. Lynch I, Weiss C, Valsami-Jones E., 2014. A strategy for grouping of nanomaterials based on key physico-chemical descriptors as a basis for safer-by-design NMs. Nano Today 9:266–70.
34. Medzhitov R., 2008. Origin and physiological roles of inflammation. Nature 454:428–35.
35. Mihalache R, Verbeek J, Graczyk H, Murashov V, van Broekhuizen P., 2017. Occupational exposure limits for manufactured nanomaterials, a systematic review. Nanotoxicology 11:7– 19.
36. Mukherjee SP, Lozano N, Kucki M, Del Rio-Castillo AE, Newman L, Vázquez E, et al. 2016. Detection of endotoxin contamination of graphene based materials using the TNF-α expression test and guidelines for endotoxin-free graphene oxide production. PLoS One 11:e0166816.
37. Naha PC, Bhattacharya K, Tenuta T, Dawson KA, Lynch I, Gracia A, et al. 2010. Intracellular localisation, geno- and cytotoxic response of polyN-isopropylacrylamide (PNIPAM) nanoparticles to human keratinocyte (HaCaT) and colon cells (SW 480). Toxicol Lett 198:134–43.
38. Nel AE, Malloy TF., 2017. Policy reforms to update chemical safety testing. Science 355:1016–18.
39. Nel AE, Nasser E, Godwin H, Avery D, Bahadori T, Bergeson L, et al. 2013. A multi-stakeholder perspective on the use of alternative test strategies for nanomaterial safety assessment. ACS Nano 7:6422–33.
40. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, et al. 2005. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122:707– 21.
41. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK., 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79– 82.
42. Rigamonti E, Chinetti-Gbaguidi G, Staels B., 2008. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma and LXRs in mice and men. Arterioscler Thromb Vasc Biol 28:1050–9.
43. Roebben G, Rasmussen K, Kestens V, Linsinger TPJ, Rauscher H, Emons H, Stamm H., 2013. Reference materials and representative test materials:the nanotechnology case. J Nanopart Res 15:1455.
44. Röszer T., 2017. Transcriptional control of apoptotic cell clearance by macrophage nuclear receptors. Apoptosis 22:284–94.
45. Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R., 2008. Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci USA 105:7387–92.
46. Vallhov H, Qin J, Johansson SM, Ahlborg N, Muhammed MA, Scheynius A, Gabrielsson S., 2006. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett 6:1682–6
47. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK., 2003. PPAR-γ and PPAR-δ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 100:6712–17.
48. Wiemann M, Vennemann A, Sauer UG, Wiench K, Ma-Hock L, Landsiedel R., 2016. An in vitro alveolar macrophage assay for predicting the short-term inhalation toxicity of nanomaterials. J Nanobiotechnol 14:16.
49. Xia T, Hamilton RF, Bonner JC, Crandall ED, Elder A, Fazlollahi F, et al. 2013. Interlaboratory evaluation of in vitro cytotoxicity and inflammatory responses to engineered nanomaterials:the NIEHS Nano GO Consortium. Environ Health tPerspect 121:683–90.